Artal Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,000,000
| Closed | -$172M | – | 160 |
|
|
2021
Q3 | $172M | Sell |
1,000,000
-400,000
| -29% | -$52.3M | 3.85% | 6 |
|
|
2021
Q2 | $176M | Hold |
1,400,000
| – | – | 3.57% | 6 |
|
|
2021
Q1 | $190M | Hold |
1,400,000
| – | – | 3.35% | 7 |
|
|
2020
Q4 | $179M | Hold |
1,400,000
| – | – | 3.85% | 5 |
|
|
2020
Q3 | $158M | Hold |
1,400,000
| – | – | 3.82% | 5 |
|
|
2020
Q2 | $133M | Sell |
1,400,000
-100,000
| -7% | -$9.64M | 3.73% | 5 |
|
|
2020
Q1 | $135M | Buy |
1,500,000
+300,000
| +25% | +$23.3M | 5.7% | 2 |
|
|
2019
Q4 | $63.6M | Sell |
1,200,000
-300,000
| -20% | -$13.7M | 2.46% | 10 |
|
|
2019
Q3 | $59.3M | Hold |
1,500,000
| – | – | 2.38% | 11 |
|
|
2019
Q2 | $61.6M | Sell |
1,500,000
-150,000
| -9% | -$6.21M | 2.49% | 10 |
|
|
2019
Q1 | $76.8M | Buy |
1,650,000
+600,000
| +57% | +$26.3M | 3.14% | 5 |
|
|
2018
Q4 | $45.7M | Buy |
1,050,000
+50,000
| +5% | +$2.5M | 1.69% | 13 |
|
|
2018
Q3 | $57.2M | Hold |
1,000,000
| – | – | 1.49% | 12 |
|
|
2018
Q2 | $48.5M | Buy |
1,000,000
+150,000
| +18% | +$5.47M | 1.03% | 13 |
|
|
2018
Q1 | $33.2M | Buy |
850,000
+100,000
| +13% | +$4.25M | 0.42% | 24 |
|
|
2017
Q4 | $31.8M | Buy |
750,000
+50,000
| +7% | +$1.88M | 0.48% | 18 |
|
|
2017
Q3 | $26.1M | Hold |
700,000
| – | – | 0.45% | 14 |
|
|
2017
Q2 | $21.3M | Sell |
700,000
-50,000
| -7% | -$1.45M | 0.37% | 25 |
|
|
2017
Q1 | $19.9M | Buy |
750,000
+600,000
| +400% | +$15.8M | 0.44% | 21 |
|
|
2016
Q4 | $3.83M | Sell |
150,000
-25,000
| -14% | -$792K | 0.09% | 60 |
|
|
2016
Q3 | $6.33M | Buy |
175,000
+75,000
| +75% | +$2.48M | 0.13% | 48 |
|
|
2016
Q2 | $3.4M | Buy |
+100,000
| New | +$3.25M | 0.07% | 51 |
|
Artal Group's XLRN Position: Q4 2021 in Review
Artal Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,000,000 shares — an estimated $172M sold.
Artal Group first reported a position in XLRN in Q2 2016 and held it in 22 quarters. The position peaked at $190M in Q1 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Artal Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Artal Group sold 1,000,000 Acceleron Pharma shares in Q4 2021, an estimated $172M.
- Artal Group first reported a position in Acceleron Pharma in Q2 2016 and held it in 22 quarters.
- Artal Group's Acceleron Pharma position peaked at $190M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.